Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Synopsis:
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size Was Valued at USD 18.3 Billion in 2023, and is Projected to Reach USD 29.9 Billion by 2032, Growing at a CAGR of 5.6% From 2024-2032.
The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is the global market of healthcare products, medicines, devices, and therapies, developed to cure COPD. COPD is a long-term respiratory illness that is marked by long-lasting breathing disorders and restrictive airflow caused by damaged lung tissues, majorly hitches from smoking, air pollution and hereditaries. Treatment considered in the market includes bronchodilators, anti-inflammatory drugs, combination therapies and non-pharmacological therapies with the main aim of controlling the symptoms, reducing the rate of progression of the illness, and enhancing the life of the patients.
COPD Treatment Market is one of the fastest growing treatment markets as the incidence of chronic respiratory diseases is rising across the world. As WHO reports, COPD is ranked as one of the main diseases that affect people’s health globally, with millions of new cases diagnosed annually. Increased emission of gases into the atmosphere, increased population age and increased rate of smoking among the people of the developing nations are some of the factors that are creating the demand for the good. Physicians and other related healthcare facility are taking their time to fill their portfolio with better treatment procedures that to some extent act asrella for COPD rather than simply making a patient go home with a prescription of inhalers. As governments and health related institutions pay attention into respiratory health, a lot of capital is being channelled towards research in the development of better drugs and treatment modalities.
Moreover, technology has developed the medical field hence improving the physical diagnosis of COPD as well as the various ways of treating the disease. They have seen a shift of combined therapies, targeted therapy and portable Inhalation devices which make it easier for patients to adhere to the doctors advise. Leading pharmaceutical firms are developing their drugs and therapies, and current ongoing clinical trials may present novel drugs and therapeutic procedures that can revolutionise the understandable, preventable management of the disease. These advancements will also directly reach the market along with the growing campaigns of awareness about the risks involves with smoking and pollutants in the surrounding atmosphere.
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Trend Analysis:
Rising Adoption of Combination Therapies
- The use of combination therapy in managing COPD is growing trend because it has shown some good results in this area of treatment. These therapies normally comprise of molecules such as bronchodilators and corticosteroids since they expand the bronchial passages while reducing inflammation collectively. Combination therapy applies to diverse aspects of COPD by offering more profound manifestations and better lung function than monotherapy. In addition, combination inhalers reduce the burden on patients through simplification of treatment regimens, and decrease hospitalisations owing to exacerbation. The general trend of rising combination treatments will likely lead the market forwards as patients and providers seek out these effective wider solutions.
Expanding Focus on Personalized Medicine
- One of the interesting opportunities present in the COPD Treatment Market is the expected growth of personalized medicine. COPD management is now possible with individualized approaches that take into consideration an individual’s genetics, lifestyle, and the environment, personalized treatment plans in COPD hold the promise for a better management. In recent years, genetic tests and biomarker study have been developed, with which the healthcare providers can know more about which treatment can be most effective for which kind of patients. This helps in the right recommendation of therapies, reduction of side effects, and the overall well-being of the patient. Drug makers are conducting extensive research and development to identify innovative diagnostic methods and targeted medications that make personalized medicine a key driver of change in the future landscape of COPD.
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Segment Analysis:
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is Segmented on the basis of Drug Class, Type, Distribution Channel, and Region
By Drug Class, Combination Therapy segment is expected to dominate the market during the forecast period
- Thus, leveraging data on the current COPD treatment market and analyzing its segments help identify that the combination therapy segment will lead during the forecast period. Long acting beta 2 agonists and inhaled corticosteroids are the combination therapies that are now recommended as the standard in the management of COPD. This two-receptor mechanism offers bronchodilation and anti-inflammatory effects necessary for ease of the disease and prevention of increased worsening in moderate to severe COPD. Patients get less frequent hospitalizations, and the therapy is more efficient for lowering shortness of breath and inflammation. Earlier this year, pharmaceutical companies started introducing new inhaler devices that can deliver these therapies more effectively and this factor is expected to sustain the recovery of this segment.
By Type, Chronic Bronchitis segment expected to held the largest share
- Analyzing the segment by type, the chronic bronchitis segment will dominate the market in the COPD Treatment Market. Chronic bronchitis is one of the COPD subtypes that involves inflammation of the airways for three months or more, causing cough with mucus. Reduction in lung function caused by this illness frequently occurs with age, and much of COPD stems from it due to the high occurrence rate, especially among smokers. Chronic bronchitis continually gains prominence as the incidence of this particular disease increases, and as new treatments are invented, moving this segment to the forefront of the market. There are ongoing efforts by companies to present new drugs and therapies for the inflammatory procedures that occur in chronic bronchitis and which fuels this segment.
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
- North America is expected to be the largest consumption market for the future of COPD treatment in 2023, which is mainly owing to the higher prevalence of patients suffering from COPD. Pertaining to the market, it is quite strong in the United States due to the increasing aging population, high level of smoking in the region, and proficient, sophisticated healthcare system. The company also noted that North America leads the regional popularity due to large pharma companies focusing on COPD and availability of better treatments. Market share of the region approximately ranges between $35 to $40 of the Global COPD Treatment Market. Furthermore, receptive governmental policies, adequate reimbursement mechanisms, as well as a structured healthcare system are also favoring the regional leadership of the market.
Active Key Players in the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market:
- AstraZeneca plc (UK)
- Boehringer Ingelheim GmbH (Germany)
- Chiesi Farmaceutici S.p.A. (Italy)
- Cipla Inc. (India)
- F. Hoffmann-La Roche AG (Switzerland)
- GlaxoSmithKline plc (UK)
- Merck & Co., Inc. (USA)
- Mylan N.V. (USA)
- Novartis AG (Switzerland)
- Orion Corporation (Finland)
- Pfizer Inc. (USA)
- Sanofi S.A. (France)
- Sun Pharmaceutical Industries Ltd. (India)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Vectura Group plc (UK)
- Other Active Players
|
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 18.3 Billion |
|
Forecast Period 2024-32 CAGR: |
5.6% |
Market Size in 2032: |
USD 29.9 Billion |
|
Segments Covered: |
By Drug Class |
|
|
|
By Type |
|
||
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market by Drug Class
4.1 Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Snapshot and Growth Engine
4.2 Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
4.3 Combination Therapy
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Combination Therapy: Geographic Segmentation Analysis
4.4 Bronchodilators
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Bronchodilators: Geographic Segmentation Analysis
4.5 Corticosteroids
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Corticosteroids: Geographic Segmentation Analysis
4.6 Phosphodiester Type 4 Inhibitor
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Phosphodiester Type 4 Inhibitor: Geographic Segmentation Analysis
4.7 Mucokinetics
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Mucokinetics: Geographic Segmentation Analysis
4.8 Others
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 Others: Geographic Segmentation Analysis
Chapter 5: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market by Type
5.1 Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Snapshot and Growth Engine
5.2 Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
5.3 Chronic Bronchitis
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Chronic Bronchitis: Geographic Segmentation Analysis
5.4 Emphysema
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Emphysema: Geographic Segmentation Analysis
Chapter 6: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market by Distribution Channel
6.1 Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Snapshot and Growth Engine
6.2 Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
6.3 Hospital Pharmacies
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospital Pharmacies: Geographic Segmentation Analysis
6.4 Retail Pharmacies
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Retail Pharmacies: Geographic Segmentation Analysis
6.5 Online Pharmacies
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Online Pharmacies: Geographic Segmentation Analysis
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share by Manufacturer (2023)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 ASTRAZENECA PLC (UK)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 BOEHRINGER INGELHEIM GMBH (GERMANY)
7.4 CHIESI FARMACEUTICI S.P.A. (ITALY)
7.5 CIPLA INC. (INDIA)
7.6 F. HOFFMANN-LA ROCHE AG (SWITZERLAND)
7.7 GLAXOSMITHKLINE PLC (UK)
7.8 MERCK & CO. INC. (USA)
7.9 MYLAN N.V. (USA)
7.10 NOVARTIS AG (SWITZERLAND)
7.11 ORION CORPORATION (FINLAND)
7.12 PFIZER INC. (USA)
7.13 SANOFI S.A. (FRANCE)
7.14 SUN PHARMACEUTICAL INDUSTRIES LTD. (INDIA)
7.15 TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL)
7.16 VECTURA GROUP PLC (UK)
7.17 OTHER ACTIVE PLAYERS
Chapter 8: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market By Region
8.1 Overview
8.2 . North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size By Drug Class
8.2.4.1 Combination Therapy
8.2.4.2 Bronchodilators
8.2.4.3 Corticosteroids
8.2.4.4 Phosphodiester Type 4 Inhibitor
8.2.4.5 Mucokinetics
8.2.4.6 Others
8.2.5 Historic and Forecasted Market Size By Type
8.2.5.1 Chronic Bronchitis
8.2.5.2 Emphysema
8.2.6 Historic and Forecasted Market Size By Distribution Channel
8.2.6.1 Hospital Pharmacies
8.2.6.2 Retail Pharmacies
8.2.6.3 Online Pharmacies
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3 . Eastern Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size By Drug Class
8.3.4.1 Combination Therapy
8.3.4.2 Bronchodilators
8.3.4.3 Corticosteroids
8.3.4.4 Phosphodiester Type 4 Inhibitor
8.3.4.5 Mucokinetics
8.3.4.6 Others
8.3.5 Historic and Forecasted Market Size By Type
8.3.5.1 Chronic Bronchitis
8.3.5.2 Emphysema
8.3.6 Historic and Forecasted Market Size By Distribution Channel
8.3.6.1 Hospital Pharmacies
8.3.6.2 Retail Pharmacies
8.3.6.3 Online Pharmacies
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4 . Western Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size By Drug Class
8.4.4.1 Combination Therapy
8.4.4.2 Bronchodilators
8.4.4.3 Corticosteroids
8.4.4.4 Phosphodiester Type 4 Inhibitor
8.4.4.5 Mucokinetics
8.4.4.6 Others
8.4.5 Historic and Forecasted Market Size By Type
8.4.5.1 Chronic Bronchitis
8.4.5.2 Emphysema
8.4.6 Historic and Forecasted Market Size By Distribution Channel
8.4.6.1 Hospital Pharmacies
8.4.6.2 Retail Pharmacies
8.4.6.3 Online Pharmacies
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5 . Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size By Drug Class
8.5.4.1 Combination Therapy
8.5.4.2 Bronchodilators
8.5.4.3 Corticosteroids
8.5.4.4 Phosphodiester Type 4 Inhibitor
8.5.4.5 Mucokinetics
8.5.4.6 Others
8.5.5 Historic and Forecasted Market Size By Type
8.5.5.1 Chronic Bronchitis
8.5.5.2 Emphysema
8.5.6 Historic and Forecasted Market Size By Distribution Channel
8.5.6.1 Hospital Pharmacies
8.5.6.2 Retail Pharmacies
8.5.6.3 Online Pharmacies
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6 . Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size By Drug Class
8.6.4.1 Combination Therapy
8.6.4.2 Bronchodilators
8.6.4.3 Corticosteroids
8.6.4.4 Phosphodiester Type 4 Inhibitor
8.6.4.5 Mucokinetics
8.6.4.6 Others
8.6.5 Historic and Forecasted Market Size By Type
8.6.5.1 Chronic Bronchitis
8.6.5.2 Emphysema
8.6.6 Historic and Forecasted Market Size By Distribution Channel
8.6.6.1 Hospital Pharmacies
8.6.6.2 Retail Pharmacies
8.6.6.3 Online Pharmacies
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7 . South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size By Drug Class
8.7.4.1 Combination Therapy
8.7.4.2 Bronchodilators
8.7.4.3 Corticosteroids
8.7.4.4 Phosphodiester Type 4 Inhibitor
8.7.4.5 Mucokinetics
8.7.4.6 Others
8.7.5 Historic and Forecasted Market Size By Type
8.7.5.1 Chronic Bronchitis
8.7.5.2 Emphysema
8.7.6 Historic and Forecasted Market Size By Distribution Channel
8.7.6.1 Hospital Pharmacies
8.7.6.2 Retail Pharmacies
8.7.6.3 Online Pharmacies
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
|
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 18.3 Billion |
|
Forecast Period 2024-32 CAGR: |
5.6% |
Market Size in 2032: |
USD 29.9 Billion |
|
Segments Covered: |
By Drug Class |
|
|
|
By Type |
|
||
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
